**S2 Table.** Studies not included in the IPD analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lead author | Year published | No. randomised | Follow-up (months) | Complete cases  |
| Artinian  | 2007 | 387 | 12 | 336 |
| Baque | 2005 | 1325 | 6 | 1057 |
| Madsen  | 2008 | 236 | 6 | 223 |
| Magid | 2011 | 326 | 6 | 283 |
| Marques-Contreras  | 2006 | 250  | 6 | 226 |
| Marques-Contreras | 2009 | 1104 | 6 | 921 |
| Marques-Contreras | 2012 | 232 | 6 | 209 |
| Rinfret | 2009 | 223 | 12 | 147 |
| Rudd  | 2004 | 150  | 6 | 137 |
| Varis | 2010 | 104 | 12 | 72 |
| Kim | 2014 | 440  | 6,12,18 | 372 (12M)383 (6M) |
| Hosseininasab | 2014 | 196 | 6 | 190 |
| Total number of not included patients with 6m follow-up+ |  | **4259** |  | **3629** |
| Total number of not included patients with primary outcome\* |  | **1154** |  | **927** |

\*Data were available from trials including 7138/8292 (86%) of patients randomised.

+ Data at six months follow-up were available from 8563/12822(67%) patients randomised.